Accelerated Pharma

Accelerated Pharma is a clinical-stage pharmaceutical company with a drug development strategy based on using genomics for personalized patient targeting. Through this approach, our proprietary drugs will be used to treat pre-selected patients to provide greater potential response to these therapies. Our business strategy is to apply this proprietary genomic platform to licensed late-stage assets with pre-existing clinical data that fit our model. Our lead product candidate, Picoplatin, is a next-generation platinum-based chemotherapy drug with extensive clinical data, showing the following characteristics: (1) overall efficacy, (2) the ability to overcome tumor resistance to other platinum drugs, and (3) significantly reduced neuropathy. We believe that combining Picoplatin with our genomic approach holds promise to significantly improve current standards of care. We are pursuing clinical testing and eventual regulatory approval for Picoplatin across multiple indications in the U.S. and other major markets.